Highlight Capital

Viva Biotech specializes in structure-based drug discovery services for biotechnology and pharmaceutical companies worldwide. Established in 2008, the company offers a range of platforms including fragment-based drug discovery, affinity selection mass spectrometry screening, and membrane protein targeted drug discovery. Its comprehensive services span from early-stage research to commercial drug delivery.

Acchrom, also known as Huapu Instrument (Beijing) Technology Co., Ltd., is a prominent company specializing in chromatography, offering comprehensive solutions that include products, technical services, and support. The company's focus is on chromatographic separation products designed to effectively separate mixtures. Acchrom emphasizes a closed-loop system that integrates chromatography equipment, consumables, software, and customer services, thereby enabling clients to conduct chromatographic separation analysis efficiently. The company is dedicated to establishing itself as a well-known national brand in chromatography and has developed targeted marketing strategies and a professional sales team across key provinces to enhance its marketing network and presence in the industry.

Silicon Innovation is a technology company based in Chengdu, China, established in December 2019. The company specializes in developing high-end interconnect chip solutions, focusing on analog and digital-analog hybrid chips tailored for clocks, interfaces, and power management. Silicon Innovation's products cater primarily to the enterprise sector, supporting critical applications in data centers, 5G communications, artificial intelligence, autonomous driving, intelligent monitoring, and the Internet of Things. By providing advanced chip technologies, the company enables businesses across various industries to enhance their systems and products, driving innovation in a rapidly evolving technological landscape.

MediLink Therapeutics is a China-based developer of antibody-drug conjugates (ADC) focused on cancer therapy. The company advances next-generation ADCs and aims to address unmet medical needs in China, while pursuing global value through multicenter clinical trials and cross-border collaborations. Its R&D center is in Suzhou.

Thousand Oaks Biopharmaceuticals, Inc., established in 2017 and headquartered in Haimen, China, specializes in contract development and manufacturing services for the biotechnology industry. The company focuses on developing technologies to produce protein and vaccine compounds, offering integrated control solutions that optimize processes, increase protein expression, and reduce production scale. Thousand Oaks provides personalized, chemically defined cell culture media, formula production, technical support, and ancillary services to its clients in the biopharmaceutical sector.

ColorTech Bio researches and develops precision molecular diagnostic equipment. It offers medical devices to improve biotechnology services and solutions. ColorTech Bio was founded in 2018 and is based in Suzhou, China.

Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

Artivila Therapeutics is a pharmaceutical company based in Shenzhen, China, founded in 2018. It specializes in the research and development of new drugs, focusing on therapeutic solutions for neurodegenerative diseases, cancers, and autoimmune diseases. The company leverages an AI-powered drug discovery engine to create an innovative platform that enables the consistent and efficient development of first-in-class molecules. Artivila Therapeutics aims to enhance patients' lives through advanced biotechnology and targeted therapeutics.

Novast is a multinational pharmaceutical company focused on the research, development, and manufacture of value-added and complex dosage forms, including controlled-release and other advanced drug-delivery systems. With operations in China and the United States, it partners with pharmaceutical and biotechnology companies to develop and commercialize products for regulated markets, providing product development services and leveraging proprietary technologies. The company emphasizes designing formulations for challenging APIs and global markets, supported by cGMP manufacturing capabilities and quality systems. It also engages in contract research, development, and quality control to support clients in achieving regulatory approval and efficient market access. Through its drug-delivery platforms and comprehensive development capabilities, Novast aims to improve access to affordable, high-quality medications while expanding its international footprint.

Xingyun Group specializes in transforming the digital supply chain for consumer goods, offering comprehensive Direct-to-Consumer (DTC) services. The company employs whole-process SaaS tools to enhance the global commodity trade environment. Its Management Middle-end System Services Engine integrates industrial ecological resources, facilitating cost reduction and efficiency improvements through data utilization. Xingyun Group supports overseas consumer brands in entering the Chinese market while assisting Chinese brands in their global expansion efforts. The platform boasts nearly 160 cooperative and self-operated warehouses across 72 countries and one region, catering to over 350,000 online and offline retailers in China. Its product offerings include maternal and child supplies, beauty care, healthcare, digital products, clothing, and shoes, ensuring reliable and cost-effective purchasing solutions for domestic retailers.

Soocas (Shenzhen) Technology Co., Ltd., founded in 2015, is an Internet technology company focused on personal digital health care products. The company emphasizes independent research and development to create advanced, intelligent, and high-quality products. Its primary offerings include the Soocas sonic electronic toothbrush and a mobile application that enhances user experience. As part of Xiaomi's ecosystem, Soocas benefits from a team with extensive experience in product design and development, drawn from notable companies such as Huawei, Oral-B, and Philips. The brand's flagship product, the X3 sonic electronic toothbrush, is backed by numerous patents in the field. With a commitment to the principles of passion, focus, and excellence, Soocas aims to continually improve its personal care products, which also include blow dryers and shaving razors.

Novast is a multinational pharmaceutical company focused on the research, development, and manufacture of value-added and complex dosage forms, including controlled-release and other advanced drug-delivery systems. With operations in China and the United States, it partners with pharmaceutical and biotechnology companies to develop and commercialize products for regulated markets, providing product development services and leveraging proprietary technologies. The company emphasizes designing formulations for challenging APIs and global markets, supported by cGMP manufacturing capabilities and quality systems. It also engages in contract research, development, and quality control to support clients in achieving regulatory approval and efficient market access. Through its drug-delivery platforms and comprehensive development capabilities, Novast aims to improve access to affordable, high-quality medications while expanding its international footprint.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

4inLook is a retailer specializing in color contact lenses, operating over 300 stores across first- and second-tier cities in China. Founded in 2008 and based in Shanghai, the company offers more than 200 distinct designs tailored primarily for women aged 18 to 30. In addition to its brick-and-mortar presence, 4inLook has expanded its reach through online channels, including a Tmall store, providing a seamless shopping experience that integrates online ordering with offline product trials and pick-up options. The company focuses on enhancing the aesthetic appeal of its customers' eyes while making cosmetic products accessible and affordable.

Genetron Health is a leading precision medicine company specializing in oncology, with a strong focus on cancer molecular profiling. The company leverages advanced technologies in molecular biology and data science to enhance cancer treatment. Genetron Health offers comprehensive health management products covering all aspects of full-cycle cancer clinical treatment, including risk assessment, early screening, molecular pathology diagnosis, medication guidance, and prognosis monitoring. They provide reliable molecular clinical services and professional cancer genetic risk assessments for patients and high-risk individuals. With global genomics sequencing and bioinformatics platforms, research and development centers in North Carolina and Beijing, and clinical laboratories across major Chinese cities, Genetron Health aims to expand its sales network throughout China. The company is dedicated to serving both Chinese and global cancer patients with its expertise in cancer genomics and efficient clinical translation.

Suzhou Kintor Pharmaceuticals is a biopharmaceutical company established in 2009, primarily engaged in the research and development of innovative drugs targeting various cancers and androgen receptor-related diseases. Headquartered in Suzhou, China, the company focuses on addressing significant unmet medical needs in conditions such as metastatic castration-resistant prostate cancer, breast cancer, and liver cancer, which collectively represent a substantial portion of the global cancer burden. Kintor's leading drug candidates include Proxalutamide, currently undergoing clinical trials for prostate and breast cancer, and Pyrilutamide, which targets androgenetic alopecia and acne vulgaris. The company also develops several other drug candidates, including ALK-1 for liver cancer and Detorsertib, a second-generation mTOR inhibitor for metastatic solid tumors. Kintor's extensive product pipeline is built on proprietary research and development, aiming to deliver both “best-in-class” and “first-in-class” therapeutic options to patients in need.

Julikang is a third-party medical device disinfection service provider focused on the healthcare industry, catering to numerous hospitals across China. The company specializes in sterilization and disinfection services, utilizing automated single and multi-chamber cleaning devices to ensure thorough sanitization of medical items and environments. Julikang enhances its service efficiency through the integration of its sterile item traceability management software with hospital information systems, allowing for real-time access to equipment manufacturer data. This capability enables effective traceability management of sterile articles, ensuring compliance and quality in disinfection processes.

Angstrom STEM is a brand of Anglia Education Group, integrating the resources and achievements of science and technology education of Shanghai Jiaotong University, and introducing the technology experience model of the United States and Canada, innovatively opening up STEM entertainment and education, integrating scientific experiments, model construction, mechanical energy, robot construction With programming, 3D printing, mathematics, etc., and focusing on the application and innovation of the latest science and technology, we have established a complete scientific STEM curriculum system to promote the quality education of domestic children and build a leading high-end STEM education brand in China.

BrightGene Bio-Medical Technology Company is a biopharmaceutical firm based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of innovative medicines and high-quality generic active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The company has a diverse product pipeline that includes immuno-oncological agents, GLP-1 receptor agonists for type 2 diabetes, and antibody-drug conjugates aimed at treating solid tumors and brain cancers. Additionally, BrightGene develops a variety of treatments such as Eribulin, Trabectedin, and various macromolecules and cytotoxic payloads. Its product offerings span multiple therapeutic areas, including oncology, cardiology, infectious diseases, and immunology. Founded in 2001, BrightGene has positioned itself as a leader in small molecules and nucleotide drugs, focusing on advancing therapeutics across all stages of development.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Chemclin Biotech is a Chinese technical service provider specializing in in-vitro diagnostic instruments and auxiliary reagents for clinical diagnosis. The company develops, produces, and sells clinical immunochemiluminescence diagnostic testing reagents and instruments. Its service offerings encompass clinical inspection instruments, various types of auxiliary reagents, technical support, management and certification, as well as the operation of independent medical laboratories. Chemclin is committed to introducing advanced diagnostic products and services to the Chinese market, thereby enhancing the capabilities of clinical diagnostics in the region.

GenFleet Therapeutics, established in 2017 and headquartered in Shanghai, China, is a biotechnology company focused on cancer research and development. It specializes in creating therapeutic molecules, including signal transduction regulators, tumor microenvironment modulators, and transcription factors, to target various cancer systems. The company aims to develop innovative molecular-level pharmaceuticals and antibody drugs that can effectively stimulate the body's immune response against tumors. GenFleet serves both domestic and international clients.

Junhetang is a prominent operator of traditional Chinese medicine clinics, specializing in a range of therapies and healthcare services. The company has established a network of clinics that provide traditional Chinese medicines, including herbal medicine, acupuncture, massage, and dietary therapies. By integrating TCM culture with the expertise of renowned practitioners, Junhetang aims to offer personalized medical services that cater to individual health needs. Additionally, the company leverages convenient internet services to enhance its healthcare management and service delivery. Headquartered in Nanjing, Junhetang is actively expanding its presence across various cities in China, including Shanghai, Shenzhen, Chengdu, and Taiyuan, thereby broadening access to traditional Chinese medicine for a wider audience.

Suzhou Kintor Pharmaceuticals is a biopharmaceutical company established in 2009, primarily engaged in the research and development of innovative drugs targeting various cancers and androgen receptor-related diseases. Headquartered in Suzhou, China, the company focuses on addressing significant unmet medical needs in conditions such as metastatic castration-resistant prostate cancer, breast cancer, and liver cancer, which collectively represent a substantial portion of the global cancer burden. Kintor's leading drug candidates include Proxalutamide, currently undergoing clinical trials for prostate and breast cancer, and Pyrilutamide, which targets androgenetic alopecia and acne vulgaris. The company also develops several other drug candidates, including ALK-1 for liver cancer and Detorsertib, a second-generation mTOR inhibitor for metastatic solid tumors. Kintor's extensive product pipeline is built on proprietary research and development, aiming to deliver both “best-in-class” and “first-in-class” therapeutic options to patients in need.

Sansure Biotech Inc. is a biotechnology company based in Changsha, Hunan Province, established in 2008. The company specializes in molecular diagnosis and genetic testing, developing and manufacturing a range of products that include nucleic acid extraction kits, real-time polymerase chain reaction (PCR) diagnostic kits, and fluorescence systems. Its product portfolio encompasses diagnostic kits for various health concerns, including novel coronavirus detection, viral hepatitis, AIDS, cancer biomarkers, and respiratory, digestive, and genetic diseases. Additionally, Sansure Biotech provides instruments and consumables to support its diagnostic offerings. The company primarily serves hospitals and laboratories both in China and internationally, focusing on enhancing diagnostic capabilities across multiple medical fields.

General Healthy is a company based in Shanghai that specializes in pharmaceutical logistics automation and mobile medical solutions. It offers a range of products and services designed for the intelligent management of medicines within the medical services and pharmaceutical circulation sectors. The company's focus is on enhancing efficiency and accuracy in the handling and distribution of pharmaceuticals, thereby improving overall healthcare delivery.

Rundo Medical is a contract research organization (CRO) that focuses on providing comprehensive clinical research outsourcing services to pharmaceutical and biotechnology companies. It specializes in a range of high-quality solutions, including clinical operations, medical data management, biostatistics, and medical project management. As a prominent player in the CRO industry, Rundo Medical is a key initiator and promoter of the China CRO Alliance. The company has distinguished itself by being the first in its sector to achieve ISO 9001:2008 quality management system certification, combined with CRO industry standard certification. Through its professional services, Rundo Medical supports various clients in advancing their medical research and operational objectives.

Tellyes Scientific Inc. is a manufacturer and marketer of healthcare equipment specifically designed for medical education and training. Established in 2001 and headquartered in Tianjin, China, the company develops a wide range of products including patient simulators, surgical simulators, ultrasound and imaging simulators, task trainers, and dental simulators, as well as offerings for traditional Chinese medicine. Tellyes Scientific also provides comprehensive solutions for planning and managing training centers, including tele-simulation services. With a focus on innovation and research, the company produces over a thousand different types of medical virtual teaching products, serving medical colleges, research organizations, and hospitals across Asia, Africa, the Middle East, Europe, North America, and Latin America.

Kontour (Xi'an) Medical Technology Co., Ltd. specializes in the research, development, production, and sale of medical devices for various surgical fields, including neurosurgery, cardiovascular surgery, craniofacial surgery, and stomatology. Established in 2005 and based in Xi'an, China, the company offers a diverse range of products. In the neurosurgery sector, it provides internal fixation titanium mesh, polyetheretherketone skull repair systems, and bioplate internal fixation systems. For thoracic surgery, Kontour Medical manufactures PEEK sternum fixation bands and rib plate systems. Its neurospine product line includes minimally invasive fixation systems and interbody fusion cages. Additionally, the company supplies oral implant systems, featuring titanium dental implants, as well as other surgical products such as hernia repair patches and lamina plates.

Genechem (China), officially known as Shanghai Genechem Co., Ltd., is a high-tech enterprise located in the Shanghai Zhangjiang Hi-Tech Park. The company specializes in providing research and development services focused on life science solutions that support gene research. It integrates various functions including genetic technology services, technological transformation, product development, and sales. Through its comprehensive offerings, Genechem aims to advance the field of genetics and contribute to innovations within the life sciences sector.

Quyi Network Technology is a technology company based in China that specializes in developing a service platform aimed at providing medical assistance. The company's platform facilitates online services, allowing users to book appointments with healthcare professionals, access lab test results, and make payments. By offering these functionalities, Quyi Network Technology enables individuals to obtain timely medical advice and information, enhancing the overall healthcare experience.

Suzhou Kintor Pharmaceuticals is a biopharmaceutical company established in 2009, primarily engaged in the research and development of innovative drugs targeting various cancers and androgen receptor-related diseases. Headquartered in Suzhou, China, the company focuses on addressing significant unmet medical needs in conditions such as metastatic castration-resistant prostate cancer, breast cancer, and liver cancer, which collectively represent a substantial portion of the global cancer burden. Kintor's leading drug candidates include Proxalutamide, currently undergoing clinical trials for prostate and breast cancer, and Pyrilutamide, which targets androgenetic alopecia and acne vulgaris. The company also develops several other drug candidates, including ALK-1 for liver cancer and Detorsertib, a second-generation mTOR inhibitor for metastatic solid tumors. Kintor's extensive product pipeline is built on proprietary research and development, aiming to deliver both “best-in-class” and “first-in-class” therapeutic options to patients in need.

Acchrom, also known as Huapu Instrument (Beijing) Technology Co., Ltd., is a prominent company specializing in chromatography, offering comprehensive solutions that include products, technical services, and support. The company's focus is on chromatographic separation products designed to effectively separate mixtures. Acchrom emphasizes a closed-loop system that integrates chromatography equipment, consumables, software, and customer services, thereby enabling clients to conduct chromatographic separation analysis efficiently. The company is dedicated to establishing itself as a well-known national brand in chromatography and has developed targeted marketing strategies and a professional sales team across key provinces to enhance its marketing network and presence in the industry.